Key Insights on Gross Profit: Halozyme Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.

Biotech Giants: Halozyme vs. Supernus Gross Profit Trends

__timestampHalozyme Therapeutics, Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 201452602000116287000
Thursday, January 1, 2015105812000136004000
Friday, January 1, 2016113485000203017000
Sunday, January 1, 2017285461000287023000
Monday, January 1, 2018141726000393541000
Tuesday, January 1, 2019150446000376095000
Wednesday, January 1, 2020224227000467938000
Friday, January 1, 2021361897000504714000
Saturday, January 1, 2022520812000580017000
Sunday, January 1, 2023636892000523742000
Monday, January 1, 2024855907000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Gross Profit Trends from 2014 to 2023

In the competitive landscape of biotechnology, Halozyme Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have shown remarkable growth in gross profit over the past decade. From 2014 to 2023, Halozyme's gross profit surged by over 1,100%, starting from a modest $52 million to an impressive $637 million. Meanwhile, Supernus Pharmaceuticals experienced a robust 350% increase, peaking at $580 million in 2022 before slightly declining to $524 million in 2023.

This period marks a significant era for both companies, with Halozyme's growth outpacing Supernus in recent years. The data highlights a pivotal shift in the biotech sector, where strategic innovations and market expansions have driven profitability. As we look to the future, these trends underscore the dynamic nature of the industry and the potential for continued financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025